II. – Les Rapports Entre Le Liquide Céphalo-Rachidien Et Les éléments Nerveux De L'axe Cerebrospinal

The blood brain barrier and Lina Solomonovna Stern (Shtern)

The blood–brain barrier (BBB) regulates the transport of molecules between the central nervous system (CNS) and blood. It consists of two components: the vascular endothelial cells forming so–called tight junctions, and the blood–cerebrospinal fluid barrier. It plays an important role in the pathogenesis and in recovery from many cerebrospinal disorders. Paul Ehrlich was the first to observe in mice that intravenously injected acidic dyes stained the tissues of the body but not the brain. He deduced there was a barrier between systemic blood and nervous tissues. His pupil Lewandowsky visualised a capillary wall that blocked the entrance of certain molecules. And, Edwin Goldman injected trypan blue into the CSF and observed that the brain but no peripheral organs was stained — indicating the dye could not cross from CSF to the systemic bloodstream, but could leave the blood vessels of the choroid plexuses within the ventricles to enter the brain tissues. Experiments of the heroic Russian Lina Solomonova Stern (Shtern), persecuted by Stalin, formulated the rule that every substance contained in the blood must penetrate the cerebrospinal fluid before it can exercise its effects on the nerve elements; she named the blood–brain barrier: barrière hémato–encéphalique.

Altered astrocytic function in experimental neuroinflammation and multiple sclerosis

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) that affects about 2.5 million people worldwide. In MS, the patients' immune system starts to attack the myelin sheath, leading to demyelination, neurodegeneration, and, ultimately, loss of vital neurological functions such as walking. There is currently no cure for MS and the available treatments only slow the initial phases of the disease. The later-disease mechanisms are poorly understood and do not directly correlate with the activity of immune system cells, the main target of the available treatments. Instead, evidence suggests that disease progression and disability are better correlated with the maintenance of a persistent low-grade inflammation inside the CNS, driven by local glial cells, like astrocytes and microglia. Depending on the context, astrocytes can (a) exacerbate inflammation or (b) promote immunosuppression and tissue repair. In this review, we will address the present knowledge that exists regarding the role of astrocytes in MS and experimental animal models of the disease.

Computational Nanoscopy of Tight Junctions at the Blood-Brain Barrier Interface

The selectivity of the blood-brain barrier (BBB) is primarily maintained by tight junctions (TJs), which act as gatekeepers of the paracellular space by blocking blood-borne toxins, drugs, and pathogens from entering the brain. The BBB presents a significant challenge in designing neurotherapeutics, so a comprehensive understanding of the TJ architecture can aid in the design of novel therapeutics. Unraveling the intricacies of TJs with conventional experimental techniques alone is challenging, but recently developed computational tools can provide a valuable molecular-level understanding of TJ architecture. We employed the computational methods toolkit to investigate claudin-5, a highly expressed TJ protein at the BBB interface. Our approach started with the prediction of claudin-5 structure, evaluation of stable dimer conformations and nanoscale assemblies, followed by the impact of lipid environments, and posttranslational modifications on these claudin-5 assemblies. These led to the study of TJ pores and barriers and finally understanding of ion and small molecule transport through the TJs. Some of these in silico, molecular-level findings, will need to be corroborated by future experiments. The resulting understanding can be advantageous towards the eventual goal of drug delivery across the BBB. This review provides key insights gleaned from a series of state-of-the-art nanoscale simulations (or computational nanoscopy studies) performed on the TJ architecture.

The rights and wrongs of blood-brain barrier permeability studies: a walk through 100 years of history

Careful examination of relevant literature shows that many of the most cherished concepts of the blood-brain barrier are incorrect. These include an almost mythological belief in its immaturity that is unfortunately often equated with absence or at least leakiness in the embryo and fetus. The original concept of a blood-brain barrier is often attributed to Ehrlich; however, he did not accept that permeability of cerebral vessels was different from other organs. Goldmann is often credited with the first experiments showing dye (trypan blue) exclusion from the brain when injected systemically, but not when injected directly into it. Rarely cited are earlier experiments of Bouffard and of Franke who showed methylene blue and trypan red stained all tissues except the brain. The term “blood-brain barrier” “Blut-Hirnschranke” is often attributed to Lewandowsky, but it does not appear in his papers. The first person to use this term seems to be Stern in the early 1920s. Studies in embryos by Stern and colleagues, Weed and Wislocki showed results similar to those in adult animals. These were well-conducted experiments made a century ago, thus the persistence of a belief in barrier immaturity is puzzling. As discussed in this review, evidence for this belief, is of poor experimental quality, often misinterpreted and often not properly cited. The functional state of blood-brain barrier mechanisms in the fetus is an important biological phenomenon with implications for normal brain development. It is also important for clinicians to have proper evidence on which to advise pregnant women who may need to take medications for serious medical conditions. Beliefs in immaturity of the blood-brain barrier have held the field back for decades. Their history illustrates the importance of taking account of all the evidence and assessing its quality, rather than selecting papers that supports a preconceived notion or intuitive belief. This review attempts to right the wrongs. Based on careful translation of original papers, some published a century ago, as well as providing discussion of studies claiming to show barrier immaturity, we hope that readers will have evidence on which to base their own conclusions.

[Dysfunction of the blood-brain barrier during ischaemia: a therapeutic concern]

Since it was discovered and its brain-protective role characterized, the blood-brain barrier (BBB), through the permeability-restricting action of the brain capillary endothelial cells, has been representing a hurdle for 95% of new medical compounds targeting the central nervous system. Recently, a BBB dysfunction is being found in an increasing number of pathologies such as brain ischaemic stroke, whose only therapy consists in a pharmacological thrombolysis limited to a small percentage of the admitted patients, because of the toxical effects of thrombolytics. And since the clinical failure of promising neuroprotectants, numerous studies of brain ischaemia were carried out, with physiopathological or pharmacological approaches refocused on the BBB, whose structural complexity is now expanded to perivascular cells, all forming a functional unit named the neurovascular unit (NVU). Nevertheless, in spite of the numerous molecular mechanisms identified, the process of BBB dysfunction in the ischaemia/reperfusion cascade remains insufficiently established to explain the pleiotropic action exerted by new pharmacological compounds, possibly protecting the entire NVU and representing potential treatments.

Developing concepts of cerebral amino acid uptake 1950-1970

This issue of the journal honors Professor Henry McIlwain for his contributions to our knowledge of neurochemistry, as a pioneer (an important contributor already in the 1950s), as a scientist, and as a teacher of great influence and help to the next generation of neurochemists. It is fitting that in his semi-retirement he turns his interest to the history and background of our discipline and demonstrates to us that there is a great deal to learn from the past. In today's explosion of knowledge and new approaches, and the consequent rush to do the work, we tend to forget not only the important past accomplishments but also the past mistakes not to be repeated. It is worthwhile from time to time to take stock, to look back at the path that led to the present. This paper is an attempt to explore this retrospection by a discussion of some of the background of research on cerebral amino acid transport. Emphasis for the purpose is on illustration, with arbitrarily selected examples rather than an exhaustive review of the subject.

Science and fate: Lina Stern (1878-1968), a neurophysiologist and biochemist

Lina Stern (1878-1968), a neurophysiologist and biochemist, was born in Russia. She studied at the University of Geneva, Switzerland, where, after graduating, she conducted original research in physiology and biochemistry. In 1918, Stern was the first woman to be awarded a professional title at the University of Geneva and headed the department of Physiological Chemistry. She is deservedly considered to be one of the first scientists to entertain the concept of a blood-brain barrier. In 1929, Stern founded the Institute of Physiology in Moscow, of which she was director until 1948, when it was discontinued. Under her leadership, multidisciplinary groups of colleagues worked on the problems of the blood-brain and tissue-brain barriers and homeostasis of the brain. In 1939, Stern was elected full member of the Academy of Sciences and became its first female member ever. Most scientists manage to conduct their research by adjusting to the political and social situations surrounding them. Lina Stern did not follow this path. This small woman of complete devotion to science took the drastic decisions that altered her life. Though destiny was not kind to her, Lina Stern did not compromise. Despite a threat of execution, prolonged imprisonment, and exile she was never broken as a scientist and always maintained her dignity.

Molecular anatomy of the blood-brain barrier as defined by immunocytochemistry

This review outlines the recent developments and improvements of our knowledge concerning the molecular composition of the BBB as revealed by immunocytochemistry. Data have been accumulated which show that the BBB exhibits a specific collection of structural and metabolic properties which are also found in tight transporting epithelia. This conclusion is substantiated by (i) the implementation of antibodies which recognize proteins of non-BBB origin, to show that these biochemical markers and the functions that they represent are localized in the BBB endothelium; and (ii) the characterization of target molecules to which polyclonal or monoclonal antibodies which have been generated to epitopes of the BBB endothelium or brain homogenates. According to these data the protein assemblies comprising the phenotypical appearance of the BBB can therefore be defined by the particular selection as well as topological expression of common epithelial antigens, rather than the expression of BBB-unique molecular species. In this respect the immunocytochemical data corroborate the physiological assumption that the BBB possesses the character of a specific polarized epithelium. Attention is also given to the description of developmental expression of BBB-related immunomarkers. By collecting the data from different sources we introduce a classification of the BBB marker proteins according to their developmental appearance. Three groups of proteins are classified with respect to their sequential expression around the time of BBB closure: Phase E (early) markers which appear before BBB closure, phase I (intermediate) markers which are expressed at the time of BBB tightening, and phase L (late) markers which are detectable after the closure of the BBB. Such a scheme may to be useful in better defining the maturation process of BBB, which apparently is not a momentary event in brain development, but rather consists of a temporally sequenced process of hierarchically structured gene expression which finally define the molecular properties of the BBB. This process continues even after parturition, especially with regard to the achievement of immunological properties of the mature BBB. By examining the developmental spatio-temporal expression of different BBB markers we conclude that the mechanisms governing the pattern of BBB maturation are not limited to the interactions occurring between glial and endothelial cells. We therefore suggest a heuristic model in a triangular interrelationship that includes differentiation effects of neurons on glia and of glia cells on the BBB endothelium.(ABSTRACT TRUNCATED AT 400 WORDS)

[Hemato-encephalic barriers. Morphologic data]

Within the cranio-spinal cavity we can consider three compartments: blood, cerebro-spinal fluid and nervous parenchyma and thus, three barriers (Blood-Cerebro-Spinal Fluid, Blood-Brain, Cerebro-Spinal Fluid-Brain). The morphological studies of these barriers were performed with exogenous tracers such as horseradish peroxidase, cytochrome C and ferritin or endogenous tracers such as autologous antiperoxidase immunoglobulins. 1. The blood-brain barrier is exogenous and endogenous tracers proof. It is found on the level of the brain capillary endothelium with tight junctions and rare plasmalemmal vesicles. 2. The blood-cerebro-spinal fluid barrier is found on the level of choroid plexus and of leptomeningeal vessel. In the former, the tracer is stopped by the tight junctions (zonula occludens type) of the choroid plexus epithelium. Besides, there is no morphological evidence of transepithelial passage from blood to cerebro-spinal fluid. In the later, the barrier is, almost always, found on the level of the vascular endothelium. 3. The parenchymatous-cerebro-spinal fluid interface cannot be called a barrier because the diffusion of the tracers is not restricted either by the astrocytic marginal layer or by the ependyma. The circumventricular organs other than choroid plexus are morphologically characterized by the free diffusion of tracers in their perivascular connective space. Subcommissural organs capillaries alone behave like those of the brain. The spinal cord capillaries, in opposition to those of the brain, are characterized by a perivascular connective space, for 40 p. 100 of them. The significance of this fact is still unknown.

Differential motor effects of intraventricular infusion of morphine and etonitazene

The motor effects produced by intraventricular infusions of morphine were compared to the effects of etonitazene. Despite the similarity in the peripheral actions of these drugs, motor effects of central infusions differed dramatically. Intraventricular morphine infusions resulted in explosive motor behavior whereas etonitazene produced extreme muscular rigidity. The periaqueductal grey (PAG) has been proposed as the substrate of morphine-induced explosive motor behavior. However, considerations of the dose of morphine and the mobility of this drug in tissue suggests that sites other than the PAG may also be involved in explosive motor behavior.